Independent LNP & RNA delivery consulting
Structure-informed consulting for biotech, pharma, and academic teams working on formulation, characterization, RNA cargo design, and biological performance.
Confidential first discussionNDA-ready when required
What clients receive
Research foundations
Years of hands-on research in lipid nanoparticles and drug delivery at the University of Amsterdam and Leiden University.
LNP development is not driven by a single parameter. RNA cargo design, lipid selection, formulation conditions, internal organization, and biological readouts must be aligned to understand why a formulation works — or fails.
We help teams identify bottlenecks, optimize formulation strategy, and decide which experiments matter most.
Recognizable development problems
Standard QC looks acceptable, but biological performance remains weak.
Similar formulations behave differently across preparations, scales, or assays.
You are unsure which methods justify the time, cost, and sample material.
Studies consume resources without revealing the underlying bottleneck.
The issue may lie in the lipid, RNA, process, assay, or biological model.
Focused scientific support
Practical, science-driven consulting tailored to your formulation and development needs.
Identify likely causes behind poor performance, instability, toxicity, or inconsistent results.
Define the analytical strategy that answers your key development questions before costly studies.
Connect formulation composition, process history, and internal organization to biological performance.
Align RNA cargo, lipid composition, process parameters, and biological readouts.
Evaluate LNP technologies, data packages, and scientific claims independently.
A mechanism-driven perspective
We combine deep scientific expertise with an independent, mechanism-driven perspective on LNP development.
We look beyond standard formulation metrics to identify the physicochemical and biological mechanisms that drive performance.
We connect formulation design, internal organization, RNA cargo, biological response, and in vivo performance rather than evaluating each in isolation.
Our recommendations are guided by the scientific question and the available evidence—not by a predefined assay package or platform.
We translate complex data into clear conclusions, prioritized next experiments, and better-informed development decisions.
How we work
Each engagement starts with the decision you need to make — then works backward to the evidence that can support it.
Review your formulation, data, constraints, and development objective.
Distinguish likely causes from convenient assumptions and missing evidence.
Translate mechanistic insight into a practical experimental or strategic roadmap.
Confidential & secure
All initial discussions are treated confidentially. For technical project details, an appropriate non-disclosure agreement can be established before sensitive information is shared as part of a future engagement.
Complementary expertise
Expertise across LNP formulation, internal structure, RNA design, synthesis, and delivery biology.
Co-founderLNP formulation, structure & delivery
Dennis supports teams with lipid nanoparticle formulation, internal structure analysis, advanced characterization, and structure–function interpretation.
Co-founderLNP formulation, RNA design & synthesis
Renzo helps teams align RNA cargo design, synthesis, analytics, and formulation compatibility.
Evidence behind the advice
Selected public research with contributions from LNPclarity team members. Follow each link to the publication or preprint record and the complete author list.
Links lipid stereochemistry and internal organization to physicochemical properties and mRNA delivery performance.
bioRxiv preprint, 2026 · Dennis Aschmann & Renzo Knol — shared first authors↗A perspective on peptide-functionalized lipid-based nanoparticles for targeted and cytosolic delivery.
Accounts of Chemical Research, 2024 · Dennis Aschmann — first author · Renzo Knol — co-author↗Compares how established ionizable lipids perform across cellular transfection and in vivo vaccination readouts.
Biomedicine & Pharmacotherapy, 2023 · Renzo Knol and Dennis Aschmann — co-authors↗Shows how LNP composition influences dendritic-cell activation and antigen-specific T-cell responses.
Biomaterials Science, 2023 · Renzo Knol — co-author↗Connects lipid phase separation with protein recognition, in vivo selectivity, and mRNA delivery.
Advanced Materials, 2024 · Renzo Knol — co-author↗Evaluates receptor-targeted LNPs for CRISPR/Cas9 delivery and cancer gene editing.
Journal of Controlled Release, 2026 · Renzo Knol — co-author↗Before getting in touch
A few practical details about enquiries, confidentiality, and the current pre-launch phase of LNPclarity.
LNPclarity is currently preparing for its formal launch. We welcome confidential enquiries and exploratory discussions. Project engagements will be confirmed once the appropriate business and institutional arrangements are in place.
Please do not share confidential details in an initial enquiry. An appropriate non-disclosure agreement can be established before sensitive information is discussed as part of a future engagement.
We welcome enquiries from academic research groups and spin-outs as well as biotechnology and pharmaceutical teams. Potential support can be discussed once the appropriate business and institutional arrangements are in place.
Independent review of existing formulation, characterization, and biological data is a core area of our planned support. The aim is to identify likely bottlenecks, missing evidence, and the most informative next steps.
No. LNPclarity currently does not undertake laboratory or paid consulting projects. Where appropriate, we may help identify independent academic research groups or CROs that clients can contact directly. Any subsequent services and contractual arrangements are agreed directly between the client and the respective provider.
A focused first conversation
Book a 30-minute confidential discovery call to explore your challenge and whether we can help.
